TuesdayAug 16, 2022 11:06 am

QualityStocksNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Releases Financial Results for H1 2022

Flora Growth (NASDAQ: FLGC), a manufacturer and distributor of global cannabis products and brands, is reporting its financial and corporate results for the six months ending June 30, 2022. Highlights of the report include revenue for the company increasing 604% from the same period last year, reaching ~$15 million while gross profit for the company increased to ~$7 million, an increase of 547%. In the report, the company reaffirmed its 2022 revenue guidance of $35 million to $45 million, which represents an increase in projected revenue of between 300% to 400%. “In the first half of 2022, Flora delivered on…

Continue Reading

MondayAug 15, 2022 12:39 pm

QualityStocksNewsBreaks – Cub Crafters Inc. Appealing to Personal Adventure Enthusiasts with Best-of-Class Backcountry Airplanes

Cub Crafters (typically styled CubCrafters) is the leading designer and manufacturer of light-sport, experimental and Part 23 certified backcountry aircraft. “Yakima, Washington-based CubCrafters has spent decades appealing to those who want to fly themselves by designing, building, testing, and selling best-of-class backcountry airplanes modeled on the classic Piper PA-18 Super Cub light aircraft, and the company’s own Cub-derived newly manufactured designs. CubCrafters offers various models of aircraft that fit under FAA Certified (Part 23), Light Sport Aircraft (‘LSA’), and Experimental Amateur Built (‘E/A-B’) classifications. CubCrafters sells finished aircraft as well as aircraft kits for experimental plane enthusiasts who enjoy the…

Continue Reading

MondayAug 15, 2022 12:32 pm

QualityStocksNewsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Files F-1 Registration

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a technology company developing solutions to optimize and automate the supply chain process and providing its Fr8App platform for B2B cross-border shipping in the NAFTA region, today announced that it has filed a Form F-1 with the SEC. “We are incredibly proud of our team and thank them for their work and dedication to deliver our F-1 registration, which positions us to be able to continue to grow as a public company. Delivering our registration statement puts us in a position to continue to work with the capital markets to foster the growth of our…

Continue Reading

MondayAug 15, 2022 12:25 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q2 2022 Financial Results, Corporate Update

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today reported its financial results for the quarter ended June 30, 2022, and provided a clinical update of its anti-cancer drug candidates currently in development. “Within the past six months alone, we have executed on a number of clinical and operational advancements including expanding our global presence with clinical approvals in Spain, France and Switzerland to drive patient enrollment forward, as well as expanding eligibility for patients to participate in our…

Continue Reading

MondayAug 15, 2022 12:17 pm

QualityStocksNewsBreaks — Laredo Oil Inc. (LRDC) Subsidiary Acquires Mineral Rights in Core Development Areas in Montana

Laredo Oil (OTC: LRDC), an oil exploration and production company, through its wholly owned subsidiary Lustre Oil Company LLC, is acquiring mineral rights in northeastern Montana core development areas. According to the company, the company has increased its acreage in these key locations from 24,000 net acres to 45,246 gross and 37,932 net acres currently.  “Our acquisition strategy has allowed us to lease acreage in the Western Williston Basin in Montana at what we believe to be a fraction of the cost of acreage in other comparable basins,” said Laredo Oil chair and CEO Mark See in the press release.…

Continue Reading

MondayAug 15, 2022 12:11 pm

QualityStocksNewsBreaks – SRAX Inc. (NASDAQ: SRAX) Announces Entry into Revolving Credit Facility, Launch of Stock Portfolio Tracker

SRAX (NASDAQ: SRAX) is a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its software-as-a-service (“SaaS”) platform. The company today announced its entry into a revolving credit facility as well as the launch of a website that allows investors to track the current value of SRAX’s marketable securities portfolio. “We are working diligently with our auditors to get our 10K filled. As of this date, there are no significant deviations (+/- 3%) on the income statement that we presented in our annual update. Our auditors have told us they believe that we will be…

Continue Reading

FridayAug 12, 2022 2:53 pm

QualityStocksNewsBreaks – Silo Pharma Inc.’s (SILO) Ketamine Study Generates ‘Extremely Promising’ Data

Silo Pharma (OTCQB: SILO), a development-stage biopharmaceutical company, recently completed an animal study of its ketamine formulation, showing nerve pain reduction when administered using a patented delivery system developed in partnership with Zylo Therapeutics. “Results from the small animal study produced positive endpoint results, demonstrating that Silo’s topical ketamine formulation reduced mechanical allodynia and hyperalgesia at both the pre- and post-dosing time points. Mechanical hyperalgesia was additionally reduced on day seven at the pre-dose time point. ‘These positive results of our study show that Silo is able to successfully formulate and deliver ketamine topically at reduced dosage to achieve its…

Continue Reading

FridayAug 12, 2022 1:29 pm

QualityStocksNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Looking to Solve Medical Challenge in Immune Responses

Aditxt (NASDAQ: ADTX) has sought to address a medical conundrum: approximately 50% of all transplanted organs are rejected by the host’s body within 10-12 years despite a wide array of medical innovations in recent years. This highlights the critical need for a practical, cost-effective solution to harmful immune responses. Aditxt is looking to solve this medical problem “through the creation of immune reprogramming technologies, which are being developed to retrain the immune system to induce tolerance to transplanted organs, self-tissues (autoimmune diseases) and allergens,” a recent article reads. “While still at a pre-clinical stage, ADi(TM) (Apoptotic DNA Immunotherapy), the company’s…

Continue Reading

FridayAug 12, 2022 1:08 pm

QualityStocksNewsBreaks – Friendable Inc.’s (FDBL) 360-Degree Offering Promoting Artists’ Independence, Revenue Generation

Friendable (OTC: FDBL), a mobile technology and marketing company, announced its acquisition of Artist Republik and FeaturedX in January 2022, bringing together a 360-degree suite of services for artists. The acquisition completed the company’s flagship offering, Fan Pass Live. “Artists can now sign up for the Fan Pass Live artist platform and benefit from music production, distribution and marketing services without the control of music labels pulling the strings or eating up revenue… The 360-degree suite of Fan Pass Live, Artist Republik and FeaturedX promotes being an independent label in an artist’s pocket, meaning there are no gatekeepers, no middleman,…

Continue Reading

FridayAug 12, 2022 12:40 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Positioning Berubicin Clinical Development Program for Success

CNS Pharmaceuticals (NASDAQ: CNSP) is currently recruiting patients for a phase II study evaluating the efficacy and safety of Berubicin, its lead drug candidate for treating glioblastoma multiforme (“GBM”), the most aggressive, deadly and treatment-resistant type of cancer that forms in the brain. Recently, the company announced that the FDA had approved an amendment to the study’s protocol, boosting its Berubicin clinical development program. “The amendment expands eligibility for its potentially pivotal study to patients who have received additional treatments as part of the first-line therapy,” explains a recent article. “The key objectives of the amendment, according to CNS Pharmaceuticals…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered